Does Aetna (CVS Health) Cover Losartan?

How Aetna (CVS Health) Formularies Categorize Losartan

Losartan potassium is a generic angiotensin II receptor blocker (ARB) approved by the FDA for hypertension, diabetic nephropathy in patients with type 2 diabetes and elevated serum creatinine, and as an adjunct in heart failure when ACE inhibitors are not tolerated. Because generic losartan has been commercially available since 2010, Aetna places it on a preferred generic tier in the majority of its plan designs. Most Aetna commercial PPO books assign losartan to Tier 1, with a copay ranging from $0 to $15 per 30-day fill depending on the specific benefit design. Some Aetna HMO products or high-deductible health plans (HDHPs) push it to Tier 2, which typically carries a $25 to $45 copay per fill. Aetna Medicare Advantage plans may classify it differently under the CMS Low Income Subsidy (LIS) rules, so beneficiaries on Medicare should pull the specific plan's Evidence of Coverage document directly from Aetna's Medicare plan finder.

The specific formulary list your plan uses is viewable through the Aetna member portal at aetna.com or through CVS Caremark's member site if your pharmacy benefits are administered by CVS Caremark. Both portals allow you to search by drug name, strength (25 mg, 50 mg, 100 mg tablets), and your plan's benefit year. Always check the current plan year's document, because formulary tier assignments can shift on January 1 of each year. The FDA prescribing information for losartan confirms the three approved indications driving coverage decisions.

Prior Authorization Criteria for Losartan on Aetna Plans

Prior authorization (PA) for a generic Tier 1 drug sounds counterintuitive, but Aetna does apply PA to losartan on some plan designs, particularly when the prescribing indication falls outside hypertension (for example, off-label heart failure monotherapy or non-diabetic proteinuria). For standard hypertension prescriptions, most Aetna commercial plans do not require PA, making it a relatively straightforward fill. The PA burden rises to moderate-high when the indication is diabetic nephropathy, because the plan may ask for documentation confirming type 2 diabetes diagnosis, a serum creatinine value, and a urine albumin-to-creatinine ratio (UACR) above 300 mg/g.

PA criteria Aetna typically requests for diabetic nephropathy coverage include:

• A confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.xx)
• Documented serum creatinine elevation (commonly >1.3 mg/dL in women or >1.5 mg/dL in men)
• UACR of 300 mg/g or higher on two separate measurements at least 90 days apart
• Notation that the prescriber has reviewed renal function and potassium levels within the past 6 months
• Documentation that an ACE inhibitor was considered, with a reason for preferring an ARB (most commonly ACE-inhibitor-induced cough, which affects roughly 10 to 15 percent of patients)

The RENAAL trial (N=1,513) published in the New England Journal of Medicine demonstrated that losartan 50 to 100 mg daily reduced the composite end point of doubling of serum creatinine, end-stage renal disease, or death by 16 percent compared with placebo in patients with type 2 diabetes and nephropathy (P<0.001). This landmark result is the clinical backbone Aetna's coverage policy references.

PA requests should be submitted by the prescribing physician through Aetna's NaviMedix portal or by fax to CVS Caremark's PA unit. Turnaround is 72 hours for non-urgent cases and 24 hours for urgent requests under URAC standards.

Step Therapy Requirements: What Aetna May Ask You to Try First

Step therapy means the insurer requires a patient to try and fail one or more alternative drugs before approving the preferred medication. Aetna's step therapy policies for losartan are plan-specific, but a common pattern seen in commercial PPO designs requires:

Step 1. A thiazide diuretic (most commonly hydrochlorothiazide 12.5 to 25 mg daily or chlorthalidone 12.5 to 25 mg daily) trialed for at least 30 days.

Step 2. An ACE inhibitor (lisinopril or enalapril) trialed for at least 30 days, unless a documented contraindication or intolerance exists.

Only after documented failure, contraindication, or intolerance of both Step 1 and Step 2 agents will Aetna release the PA hold on losartan under step therapy rules. Patients with bilateral renal artery stenosis, prior angioedema with an ACE inhibitor, or hyperkalemia (serum potassium above 5.5 mEq/L) on a diuretic qualify for step therapy exemptions. The prescriber must document these conditions in the PA request letter.

The LIFE trial (Lancet 2002, N=9,193) compared losartan 50 to 100 mg to atenolol 50 to 100 mg in hypertensive patients with left ventricular hypertrophy and found a 13 percent relative risk reduction in the primary composite of cardiovascular death, stroke, or myocardial infarction favoring losartan (P=0.021), with a particularly strong 25 percent relative risk reduction in stroke. This cardiovascular superiority data is frequently used by prescribers to justify bypass of beta-blocker step therapy.

If your physician believes step therapy is medically inappropriate for your specific case, they can request a step therapy exemption or "clinical exception" at the time of the initial PA submission. Many states now have step therapy reform laws mandating that insurers grant exceptions within 72 hours when a physician attests clinical necessity.

HealthRX Step Therapy Override Decision Framework for Losartan

Use the following sequence when preparing a step therapy exemption request for a patient denied losartan under Aetna step therapy rules:

1. Confirm the patient has not previously failed the required step agents (if they have failed them, document dates, doses, and outcomes).
2. Identify any contraindication to the step agent: ACE inhibitor contraindications include prior angioedema, bilateral renal artery stenosis, or pregnancy; thiazide contraindications include sulfonamide allergy or gout with recurrent flares.
3. Pull current labs: basic metabolic panel (potassium, creatinine, eGFR) and UACR if nephropathy is the indication.
4. Write a one-page clinical justification letter referencing the RENAAL trial data for nephropathy or the LIFE trial data for LVH-associated hypertension.
5. Submit to Aetna CVS Caremark PA fax line with the clinical letter, relevant lab results, and ICD-10 diagnosis codes attached.
6. Follow up at 48 hours if no decision is received.

Appealing an Aetna Denial of Losartan

A denial letter from Aetna must include the specific reason for denial, the clinical criteria applied, and instructions for filing an appeal. Federal law under the ACA requires insurers to acknowledge an internal appeal within 72 hours of receipt and issue a decision within 30 days for non-urgent cases (or 72 hours for urgent cases).

Level 1 Internal Appeal. The prescribing physician submits a written appeal packet. This should include a cover letter stating the clinical rationale, copies of relevant lab results, any peer-reviewed literature supporting medical necessity (RENAAL for nephropathy, LIFE for LVH/hypertension), office notes from the past 12 months, and the patient's medication history showing prior drug trials. Aetna's internal medical reviewers are board-certified physicians, but they review these cases quickly. A thorough packet increases approval odds substantially.

The American Heart Association's 2023 Guideline for the Diagnosis and Treatment of Heart Failure states: "ARBs are recommended for patients with HFrEF who cannot tolerate ACE inhibitors due to cough or angioedema (Class I, Level of Evidence A)." Citing this guideline language directly in the appeal letter gives the reviewer a guideline-level mandate to approve.

Level 2 External Independent Review. If the internal appeal is denied, Aetna must offer an external review by an independent review organization (IRO) accredited by URAC or NCQA. The IRO's decision is binding on Aetna under most state laws. External reviews overturn initial denials at rates ranging from 30 to 40 percent for medication-related cases, according to data from state insurance department annual reports.

State Insurance Commissioner Complaint. Filing a complaint with your state's insurance commissioner simultaneously with the Level 2 external review creates a paper trail that sometimes accelerates Aetna's internal reconsideration. This step costs nothing and takes under 20 minutes online.

Key documents to prepare for any appeal:

• The denial letter itself (cite the specific denial code and criteria language)
• A prescriber attestation letter (written, signed, on office letterhead)
• Labs: BMP, UACR, HbA1c if diabetic nephropathy is the indication
• Prior drug trial records if step therapy is cited
• Relevant guideline excerpts (AHA, JNC8, ADA Standards of Care)

The ADA Standards of Medical Care in Diabetes (2024) states: "In patients with type 2 diabetes, hypertension, and diabetic kidney disease, an ACE inhibitor or ARB at the maximum tolerated dose is recommended (Grade A)." That Grade A recommendation carries significant weight in overturning a PA or step therapy denial.

What Losartan Costs Without Aetna Coverage

If your claim is denied and you need the medication immediately, cash-pay pricing for generic losartan is genuinely low. The 50 mg tablet at 30 count runs approximately $10 to $14 per month at CVS Pharmacy using the CVS Health Savings Program or GoodRx coupons. The 100 mg tablet at 30 count is similarly priced at $12 to $18 per month at most major pharmacy chains. At these prices, many patients find it cheaper to pay cash and skip the insurance claim entirely, at least while the appeal is pending.

Brand-name Cozaar (losartan potassium, manufactured by Organon) carries a list price near $80 per month and is rarely covered at preferred tier rates on commercial plans. Most Aetna formularies either exclude Cozaar entirely (non-formulary) or place it at Tier 4 or Tier 5 with a specialty copay, making the generic the practical choice in almost every case.

Organon does not currently operate a broad manufacturer patient assistance program for Cozaar aimed at commercially insured patients, unlike GLP-1 receptor agonists or newer branded medications. Patients with household incomes below 200 percent of the federal poverty level may qualify for state pharmaceutical assistance programs or the Organon Patient Assistance Program (PAP) for uninsured patients. PAP eligibility does not apply while any active insurance coverage is in force for the drug.

Clinical Background: Why Losartan Is Prescribed and Why Coverage Matters

Losartan potassium blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction and aldosterone secretion. At 50 mg once daily, it produces a mean reduction in systolic blood pressure of 5.5 to 10.5 mmHg versus placebo in placebo-controlled trials. Titration to 100 mg once daily adds an additional 3 to 5 mmHg reduction in some patients. The FDA-approved prescribing information describes the full pharmacodynamic profile.

Three indications drive the vast majority of prescriptions, and each has a distinct evidence base that matters for coverage arguments:

Hypertension. The Joint National Committee and AHA/ACC 2017 Hypertension Guidelines recommend ARBs as first-line agents in patients with compelling indications (CKD, diabetes, LVH) and as acceptable first-line alternatives in the broader hypertensive population. This broad guideline support makes blanket denials for hypertension medically indefensible, and Aetna rarely denies losartan for uncomplicated hypertension.

Diabetic nephropathy. The RENAAL trial remains the definitive evidence. Losartan 50 to 100 mg daily reduced the risk of the primary composite end point (doubling of serum creatinine, ESRD, or death) by 16 percent (P<0.001) and reduced ESRD alone by 28 percent (P=0.002) in 1,513 patients with type 2 diabetes and nephropathy over a mean follow-up of 3.4 years. These are the specific numbers to cite in a PA request.

Heart failure (HFrEF). The ELITE II trial (Lancet 1999, N=3,152) compared losartan 50 mg to captopril in elderly heart failure patients and found no significant difference in all-cause mortality between groups (P=0.16), but losartan was significantly better tolerated (fewer discontinuations due to adverse effects). This equivalence-with-better-tolerability profile supports ARB use in ACE-inhibitor-intolerant HFrEF patients and is the basis for the AHA's Class I, Level A recommendation cited earlier.

Practical Steps to Get Losartan Covered Through Aetna

Patients and prescribers who follow a structured approach resolve most Aetna losartan coverage issues within 7 to 14 days. Here is the sequence that works:

Step 1. Confirm your plan formulary. Log in to aetna.com or cvs.com/caremark, search "losartan potassium," and note the tier and any PA or step therapy flags on your specific plan. Screenshot the result and save it with the date.

Step 2. Ask the prescriber to submit PA at the time of prescribing. Many electronic prescribing platforms (Epic, DrFirst) support real-time PA submission to Aetna CVS Caremark. Same-day PA submission prevents a gap in therapy.

Step 3. Gather labs before the PA is filed. A BMP with creatinine and potassium, a UACR, and an HbA1c (if diabetic nephropathy) should be attached to the PA. Missing labs are the most common reason for PA delays.

Step 4. If denied, request the denial in writing immediately. You have the right to a written denial with the specific criteria applied. Do not accept a verbal denial without documentation.

Step 5. File the Level 1 internal appeal within 180 days of denial (the ACA deadline). Use the framework above to build the appeal packet.

Step 6. Fill a 30-day cash-pay supply while the appeal is pending. At $10 to $14 per 30 count, continuity of antihypertensive therapy is far safer than a coverage gap. Uncontrolled hypertension raises the risk of stroke, and the CDC notes that only about 1 in 4 adults with hypertension has their blood pressure adequately controlled in the United States. Maintaining therapy during coverage disputes is a patient safety priority.

If the Level 1 appeal is denied, file the external IRO review within 4 months (federal deadline) and simultaneously contact your state insurance commissioner. Most patients with a well-documented PA request resolved through this pathway within 30 to 45 days total. The generic's low cash price means out-of-pocket exposure during the process is manageable for most commercially insured patients.